News
1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?
Per Cantor Fitzgerald analyst Louise Chen's calculations published March 4, Pfizer's (NYSE: PFE) stock is going to climb by around 75% to reach or surpass $45 over the coming quarters. Chen's
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
The day after Intellia Therapeutics (NASDAQ: NTLA) updated investors with its results for the fourth quarter on Feb. 23, Cannacord Genuity analyst Whitney Ijem issued a new price target for the
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (NYSE: LLY) is already giving Novo Nordisk (NYSE: NVO) a run for its money with the approval in the
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305810568/en/
(Graphic: Business Wire)
GenSight Biologics
EQS-News: Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NYSE:NVO), thanks to its type 2
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
The gold rush for anti-obesity medicines is here, and the stakes are high. Per a report by Morgan Stanley Research, the market for weight loss drugs will be worth around $77 billion by 2030, despite
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process
1 S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Keep winners, ditch losers. That's usually not bad advice for investors. There's one big problem, though: Sometimes long-term winners temporarily look like losers.
Even the biggest and the best
1 S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Keep winners, ditch losers. That's usually not bad advice for investors. There's one big problem, though: Sometimes long-term winners temporarily look like losers.
Even the biggest and the best
1 Wall Street Analyst Thinks Viking Therapeutics Stock Is Going to $116. Is It a Buy Around $81?
With shares of Viking Therapeutics (NASDAQ: VKTX) flying 555% higher in the last three months, at least one financial analyst is saying that it can go even higher. On Feb. 28, Oppenheimer's Jay
Is Novavax a Buy Now?
Novavax (NASDAQ: NVAX) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
Anti-obesity drugs rose in popularity last year, helping the leaders in this market -- notably Eli Lilly and Novo Nordisk -- crush the market. However, some medical device specialists got the wrong
Better Buy: Eli Lilly vs. Viking Therapeutics
Comparing Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) might initially seem odd. The two drugmakers don't seem to have much in common. Eli Lilly is more than 50 times the size of
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
After rising by 137% in one day upon the publication of favorable phase 2 clinical trial results on Feb. 27, Viking Therapeutics (NASDAQ: VKTX) is now doubtlessly on many investors' radars. Soon
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Given its key role in the fight against COVID-19, the fact that Pfizer (NYSE: PFE) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Given its key role in the fight against COVID-19, the fact that Pfizer (NYSE: PFE) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
Technically, there is no upper limit to how much money investors can make from stocks in five years, but turning $1,000 into $2,500 is no easy task. That requires a compound annual growth rate
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Since 2021, shares of Novavax (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the